Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 2,827 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) CAO Alexander Azoy sold 2,827 shares of the firm’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $30.00, for a total value of $84,810.00. Following the transaction, the chief accounting officer owned 39,581 shares in the company, valued at approximately $1,187,430. This represents a 6.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alexander Azoy also recently made the following trade(s):

• On Monday, June 1st, Alexander Azoy sold 2,562 shares of Arcus Biosciences stock. The shares were sold at an average price of $25.77, for a total value of $66,022.74.

Arcus Biosciences Stock Down 0.5%

NYSE:RCUS traded down $0.14 during mid-day trading on Monday, reaching $30.20. The company’s stock had a trading volume of 1,296,258 shares, compared to its average volume of 1,246,869. The company has a quick ratio of 3.82, a current ratio of 3.82 and a debt-to-equity ratio of 0.22. Arcus Biosciences, Inc. has a 1 year low of $10.07 and a 1 year high of $31.74. The stock has a fifty day moving average of $28.50 and a 200-day moving average of $24.78. The firm has a market capitalization of $3.85 billion, a PE ratio of -7.74 and a beta of 0.80.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.17. Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The business had revenue of $41.00 million during the quarter, compared to analyst estimates of $21.98 million. The company’s quarterly revenue was down 74.4% on a year-over-year basis. Equities research analysts forecast that Arcus Biosciences, Inc. will post -3.53 earnings per share for the current year.

Institutional Trading of Arcus Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC boosted its holdings in Arcus Biosciences by 10.0% in the 2nd quarter. GAMMA Investing LLC now owns 3,966 shares of the company’s stock worth $122,000 after buying an additional 359 shares during the last quarter. Royal Bank of Canada lifted its position in shares of Arcus Biosciences by 14.6% in the first quarter. Royal Bank of Canada now owns 4,758 shares of the company’s stock valued at $102,000 after acquiring an additional 607 shares in the last quarter. Creative Planning boosted its stake in shares of Arcus Biosciences by 2.7% in the third quarter. Creative Planning now owns 29,629 shares of the company’s stock worth $403,000 after acquiring an additional 771 shares during the last quarter. Hantz Financial Services Inc. increased its position in shares of Arcus Biosciences by 121.9% during the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock worth $38,000 after purchasing an additional 881 shares in the last quarter. Finally, New York State Teachers Retirement System increased its position in shares of Arcus Biosciences by 1.1% during the fourth quarter. New York State Teachers Retirement System now owns 92,431 shares of the company’s stock worth $2,203,000 after purchasing an additional 1,000 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on RCUS shares. The Goldman Sachs Group reiterated a “buy” rating and issued a $42.00 price target on shares of Arcus Biosciences in a report on Friday, August 7th. Wall Street Zen downgraded Arcus Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. HC Wainwright lifted their target price on Arcus Biosciences from $32.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Morgan Stanley set a $23.00 target price on shares of Arcus Biosciences in a report on Monday, August 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Friday, July 17th. Eight equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $37.80.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.